Ontology highlight
ABSTRACT:
SUBMITTER: Bakulin I
PROVIDER: S-EPMC4033290 | biostudies-literature | 2014 May
REPOSITORIES: biostudies-literature
Bakulin Igor I Pasechnikov Victor V Varlamicheva Anna A Sannikova Irina I
World journal of hepatology 20140501 5
A new treatment paradigm for hepatitis C is that the treatment must include an existing direct-acting antiviral agent, namely, a protease inhibitor (PI) combined with PEGylated interferon-α and ribavirin. The currently marketed PIs and PIs in clinical trials have different mechanisms of action. The development of new PIs aims for an improved safety profile and higher effectiveness. This article reviews NS3/4A protease inhibitors, focusing on major criteria such as their effectiveness and safety. ...[more]